Alcon announces closing of acquisition of Belkin Vision


Belkin Vision is the developer of Vision Eagle direct selective laser trabeculoplasty technology.

Business meeting in office Image Credit: AdobeStock/alfa27

Image Credit: AdobeStock/alfa27

Alcon has announced completion of its acquisition of Belkin Vision, developer of the Belkin Vision Eagle direct selective laser trabeculoplasty (DSLT) for the treatment of glaucoma. The companies have agreed to a total upfront consideration of $81 million USD, including a cash payment of approximately $65 million, according to a news release. The deal also includes the potential for up to $385 million in payments, which is contingent on sales-based milestones.1

“As a therapy with significant advantages for the patient and practice, we believe our newly acquired DSLT technology is uniquely positioned to accelerate the evolution toward first-line use of SLT in the glaucoma treatment paradigm,” said Sean Clark, president of Global Surgical Franchise at Alcon, in the release. “We look forward to broadening access to this exciting technology in the future as we continue to address solutions for unmet needs in glaucoma.”

The acquisition includes the DSLT technology, which works in a similar fashion to traditional SLT by delivering laser energy to the trabecular meshwork. DSLT technology, however, includes proprietary eye-tracking technology for accurate, automated treatment delivery through the limbus, which eliminates the needs for a gonio lens or manual aiming, according to the release.1

“Despite ample evidence for SLT as primary therapy in glaucoma treatment, practical challenges limit availability to many patients who could benefit from it,” said Nathan M. Radcliffe, MD, in the release. “DSLT will have a profound impact on laser-first, helping to overcome these barriers and meaningfully improve access to laser therapy — shifting doctor and patient perceptions around efficiency and comfort.”

Belkin’s DSLT technology has been approved in the EU and UK, and has receive 510(k) clearance from the US FDA, but is not available yet in the US. Alcon plans to continue supplying DSLT technology in the EU and UK and aims to have the device available to eye care providers in the US by the end of 2024.1

  1. Alcon completes acquisition of Belkin Vision, expanding glaucoma portfolio with direct selective laser trabeculoplasty (DSLT) device. Alcon. July 1, 2024. Accessed July 2, 2024.
Related Videos
Spencer Johnson, OD, FAAO, overviews his talk on laser procedures at Optometry's Meeting
Drs Erin Draper and Chris Cuk outline the important role optometrists have in spotting neurodegenerative disease in patients
Raman Bhakhri, OD, FAAO, overviews his talk on medications' potential side effects on the retina with Optometry Times
Jade Coats, OD, overviews a lecture on ocular pain and patient care
Jade Coats, OD, outlines two poster presentations she gave on a novel lipid-containing eye drop at the AOA Optometry's Meeting
Adam Alexander, OD, chats with Optometry Times about his AOA e-poster presentation on Miebo
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Edmund Tsui, MD, details what insights swept-source anterior segment OCT images may give to determining eye inflammation
© 2024 MJH Life Sciences

All rights reserved.